TAE Life Sciences is advancing a new frontier in radiation oncology with its next-generation Boron Neutron Capture Therapy (BNCT) platform. By combining tumour-targeted boron compounds with precise neutron delivery, BNCT offers the potential to treat refractory and recurrent cancers with highly selective cell-level damage.​ ​ Through Transmedic, TAE Life Sciences brings this emerging technology closer to centres in Southeast Asia, supporting the development of a treatment approach designed for patients with few remaining options.